NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Corvus Pharmaceuticals, Inc. (CRVS) Stock Analysis

Corvus Pharmaceuticals, Inc. (CRVS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CRVS

$10.05

−$0.18 (−1.76%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CRVS with… →

CRVS Key Statistics

As of Oct 21, 2026
Trading
Open
$10.25
Previous Close
$10.23
Day's Range
10.01–10.59
52-Week Range
6.39–26.95
Volume
868.56K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.43
Valuation
Market Cap
$845.42M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.62
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$15.28M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
84.12M
1-Year Return
+39.58%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
985.65K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CRVS closed at $10.05, +39.58% over 1 year.

Corvus Pharmaceuticals, Inc. (CRVS) has a market capitalization of $845.42M.

In fiscal 2025, CRVS reported revenue of $0.00.

CRVS Stock Return by Calendar Year

Corvus Pharmaceuticals, Inc. (CRVS) 10-year return: what $10,000 became

1 year
$10,000 $13,958
+39.58%
5 years
$10,000 $20,981
+109.81%
10 years
$10,000 $6,955
−30.45%

If you had invested $10,000 in Corvus Pharmaceuticals, Inc. (CRVS) 10 years ago, at the close on October 21, 2016, it would have been worth $6,955 at the close on October 21, 2026: −30.45% in total, −3.57% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+30.52%
2025+43.93%
2024+203.98%
2023+107.06%
2022−64.73%
2021−32.30%
2020−34.56%
2019+48.23%
2018−64.58%
2017−27.55%
2016 (partial year)+3.70%

As of October 21, 2026.

CRVS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$15.28M—
2024$0.00−$62.29M—
2023$0.00−$27.03M—
2022$0.00−$41.31M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$42.97M−$15.28M—
2024$0.00—−$27.55M−$62.29M—
2023$0.00—−$23.41M−$27.03M—
2022$0.00—−$32.57M−$41.31M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Corvus Pharmaceuticals, Inc. (CRVS) is capitalised at $845.42M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 37 employees.

The 52-week range on file runs from $6.39 to $26.95. The most recent close on file for CRVS is $10.05, dated October 21, 2026. That is −$0.18 (−1.76%) against the previous close. The latest close sits 57.28% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $15.28M. Earnings per share on a trailing basis come to −0.62.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 1.43. Daily returns over the trailing 10 years annualize to a volatility of 111.39%. The trailing one-year total return is +39.58%. Measured over 10 years, that is −3.57% a year compounded.

Growth & Income

No dividend is on file for CRVS.

So far in 2026 the total return is +30.52%. The strongest complete calendar year on file is 2024 at +203.98%; the weakest is 2022 at −64.73%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Corvus Pharmaceuticals, Inc. (CRVS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Corvus Pharmaceuticals, Inc. CRVS $845.42M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Corvus Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.

Visit website →